Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

BACKGROUND: Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic disturbances. Additionall...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Julie Rask, Vedtofte, Louise, Holst, Jens Juul, Oturai, Peter, Kjær, Andreas, Corell, Christoph U, Vilsbøll, Tina, Fink-Jensen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975765/
https://www.ncbi.nlm.nih.gov/pubmed/24667381
http://dx.doi.org/10.1136/bmjopen-2013-004227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975765/
https://www.ncbi.nlm.nih.gov/pubmed/24667381
http://dx.doi.org/10.1136/bmjopen-2013-004227

Ejemplares similares